What is Diltiazem?
Diltiazem is a widely prescribed medication belonging to the dihydropyridine class of calcium channel blockers. It plays a crucial role in managing various cardiovascular conditions by affecting the movement of calcium ions into heart and blood vessel cells. This action helps to relax blood vessels, reduce heart rate, and decrease the heart's workload, thereby improving blood flow and easing symptoms associated with conditions like hypertension, angina, and certain arrhythmias. Available in both generic forms and under various brand names such as Cardizem®, Tiazac®, and others, diltiazem offers a flexible treatment option for patients with diverse cardiovascular needs. Understanding its pharmacological profile, clinical applications, and potential risks is essential for healthcare providers and patients alike.
Mechanism of Action
Diltiazem exerts its therapeutic effects by selectively inhibiting the influx of extracellular calcium ions across the membranes of myocardial cells and vascular smooth muscle cells. It primarily targets L-type calcium channels, which are voltage-gated ion channels responsible for mediating the slow inward calcium current. By binding to these channels, diltiazem stabilizes the resting membrane potential and reduces the number of open channels, thereby decreasing intracellular calcium concentration.
Effects on the Cardiovascular System:
- Vasodilation: In vascular smooth muscle, the reduction in intracellular calcium leads to relaxation of the muscle, resulting in peripheral and coronary vasodilation. This lowers systemic vascular resistance (afterload), which can reduce blood pressure and improve blood flow to the heart muscle.
- Negative Chronotropy: In the sinoatrial (SA) node, diltiazem slows the rate of spontaneous depolarization, leading to a decrease in heart rate (negative chronotropy). This effect is due to the reduced influx of calcium ions, which are essential for the pacemaker potential.
- Negative Inotropy: In the atrioventricular (AV) node and, to a lesser extent, in the myocardium, diltiazem slows down the conduction of electrical impulses and reduces the force of contraction (negative inotropy). The effect on AV nodal conduction is particularly significant, helping to control rapid ventricular rates in atrial fibrillation and flutter.
These combined actions make diltiazem a valuable agent in managing conditions where excessive vascular tone, inadequate coronary blood flow, or rapid heart rates are contributing factors.
Clinical Uses & Indications
The Food and Drug Administration (FDA) has approved diltiazem for the treatment of several significant cardiovascular conditions. Its efficacy in managing high blood pressure, chest pain, and irregular heart rhythms makes it a cornerstone therapy in cardiology.
Hypertension
Diltiazem is indicated for the management of essential hypertension. By causing vasodilation, it reduces peripheral vascular resistance, leading to a decrease in both systolic and diastolic blood pressure. It can be used as monotherapy or in combination with other antihypertensive agents, such as diuretics or ACE inhibitors, to achieve target blood pressure goals.
Angina Pectoris
Diltiazem is effective in the chronic management of angina pectoris due to coronary artery spasm (Prinzmetal's angina) and in the management of classic (stable) angina. By dilating coronary arteries, it increases oxygen supply to the myocardium. Simultaneously, by reducing heart rate and contractility, it decreases myocardial oxygen demand. This dual action helps to prevent anginal episodes and improve exercise tolerance.
Arrhythmias
Diltiazem is indicated for the control of rapid ventricular response in patients with atrial fibrillation or atrial flutter. It acts on the AV node to slow conduction, thereby reducing the ventricular rate and improving hemodynamic stability. It is also used for the treatment of paroxysmal supraventricular tachycardia (PSVT) originating above the ventricles.
Dosage & Administration
Diltiazem is available in various dosage forms, including immediate-release capsules, extended-release capsules, tablets, and intravenous (IV) injection. The choice of formulation and dosage depends on the specific indication, patient response, and desired duration of action.
Dosage Forms and Routes:
- Oral Formulations:
- Immediate-Release: Typically administered three to four times daily. Doses usually range from 30 mg to 90 mg per dose.
- Extended-Release (ER/CD/LA): Designed for once or twice-daily dosing, offering improved patient compliance and more consistent plasma levels. Strengths vary, commonly from 60 mg to 420 mg per day, depending on the specific product formulation (e.g., Tiazac, Cardizem CD).
- Intravenous (IV) Administration: Used for rapid control of heart rate in atrial fibrillation/flutter or for acute management of PSVT. It can be administered as a bolus injection followed by a continuous infusion.
General Dosing Considerations:
- Dosage should be individualized based on the patient's clinical response, blood pressure, heart rate, and renal or hepatic function.
- Initiation of therapy often begins with a low dose, which is then gradually increased as needed.
- For patients with hepatic or renal impairment, lower starting doses and careful monitoring are recommended due to potential for increased drug exposure.
- Extended-release formulations should not be crushed or chewed but swallowed whole.
Side Effects & Safety
While diltiazem is generally well-tolerated, like all medications, it can cause side effects. The incidence and severity of these effects can vary depending on the dose, formulation, and individual patient factors.
Common Side Effects:
The most frequently reported side effects are generally mild and related to its vasodilatory and cardiac effects:
- Edema (swelling, particularly in the ankles and feet)
- Headache
- Dizziness or lightheadedness
- Nausea
- Rash
- Fatigue or somnolence (drowsiness)
- Bradycardia (slow heart rate)
- Hypotension (low blood pressure)
Serious Side Effects:
More severe adverse events, though less common, require prompt medical attention:
- Significant Bradycardia or AV Block: Diltiazem can worsen pre-existing conduction abnormalities or cause severe slowing of the heart rate, potentially leading to syncope or cardiac arrest.
- Congestive Heart Failure: In patients with compromised left ventricular function, the negative inotropic effects of diltiazem can exacerbate heart failure.
- Hepatotoxicity: Although rare, liver enzyme elevations and hepatocellular injury have been reported.
- Hypersensitivity Reactions: Including Stevens-Johnson syndrome and toxic epidermal necrolysis.
- Gastrointestinal Bleeding: Particularly when used concurrently with NSAIDs.
Contraindications and Precautions:
Diltiazem is contraindicated in patients with:
- Severe hypotension
- Recent myocardial infarction and pulmonary congestion
- Sick sinus syndrome (except in patients with a functioning artificial pacemaker)
- Second- or third-degree AV block (except in patients with a functioning artificial pacemaker)
- Known hypersensitivity to diltiazem
- Cardiogenic shock
Caution should be exercised in patients with impaired hepatic or renal function, and in those with conditions that may be exacerbated by bradycardia or AV block.
Drug Interactions
Diltiazem can interact with a number of other medications, altering their efficacy or increasing the risk of adverse effects. This is often due to its metabolism by the cytochrome P450 enzyme system, particularly CYP3A4.
Notable Interactions:
- Other Cardiovascular Drugs: Concurrent use with beta-blockers or digoxin can increase the risk of bradycardia and AV block. Statins (e.g., atorvastatin, simvastatin) that are CYP3A4 substrates can have their plasma concentrations significantly increased by diltiazem, raising the risk of myopathy.
- CYP3A4 Inhibitors: Drugs that inhibit CYP3A4 (e.g., certain antifungals like ketoconazole, macrolide antibiotics like erythromycin, protease inhibitors) can increase diltiazem levels, potentially leading to toxicity.
- CYP3A4 Inducers: Drugs that induce CYP3A4 (e.g., rifampin, carbamazepine, phenytoin) can decrease diltiazem levels, reducing its effectiveness.
- Grapefruit Juice: Consumption of grapefruit juice can inhibit CYP3A4 in the intestinal wall, leading to increased absorption and plasma levels of diltiazem.
- Anesthetics: Additive negative inotropic and chronotropic effects can occur with general anesthetics.
It is crucial for patients to inform their healthcare providers about all medications, including over-the-counter drugs and herbal supplements, they are currently taking to avoid potentially dangerous interactions.
Molecular Properties
Understanding the molecular characteristics of diltiazem provides insight into its pharmacokinetic and pharmacodynamic properties.
- Chemical Name: (2S,3S)-3-acetoxy-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one
- Molecular Formula: C22H26N2O4S
- Molecular Weight: 414.52 g/mol
- SMILES Notation:
COc1ccc([C@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1
Structure Description:
Diltiazem is a benzothiazepine derivative. Its structure features a central seven-membered ring containing both sulfur and nitrogen atoms, fused to a benzene ring. Key functional groups include an acetoxy group, a tertiary amine side chain, and a methoxy-substituted phenyl ring. The molecule possesses two chiral centers, contributing to its stereospecific interaction with calcium channels. The SMILES notation provided encapsulates this complex three-dimensional structure, detailing the connectivity and stereochemistry of its atoms.
Analyze Diltiazem with MolForge
Exploring the intricate molecular landscape of diltiazem, from its detailed structural features to its complex interactions within biological systems, is essential for drug discovery and development. MolForge's AI-powered platform offers advanced tools to delve deeper into such molecules. Researchers can leverage MolForge to analyze diltiazem's properties, predict potential metabolites, explore structure-activity relationships, and identify novel analogs with improved therapeutic profiles. Discover the power of AI in accelerating your molecular research. Visit our dashboard to start analyzing diltiazem and other molecules today.